Germline substitutions in the endothelial cell tyrosine kinase receptor TIE2 (encoded by TEK) cause a rare, inherited form of venous anomaly known as a mucocutaneous venous malformation (VMCM; refs. 1-3 and V.W., N.L., M.U., A. Irrthum, L.M.B. et al., unpublished data). We identified a somatic 'second hit' causing loss of function of TIE2 in a resected VMCM and assessed whether such localized, tissue-specific events have a role in the etiology of sporadic venous malformations, which are far more common. We identified eight somatic TEK mutations in lesions from 28 of 57 individuals (49.1%) with sporadic venous malformations; the mutations were absent from the individuals' blood and control tissues. The somatic mutations included one causing a frequent L914F substitution and several double mutations in cis, all of which resulted in ligand-independent TIE2 hyperphosphorylation in vitro. When overexpressed in human umbilical vein endothelial cells, the L914F mutant was abnormally localized and responded to ligand, in contrast to wild-type TIE2 and the common, inherited R849W mutant, suggesting that the mutations have distinct effects. The presence of the same mutations in multifocal sporadic venous malformations in two individuals suggests a common origin for the abnormal endothelial cells at the distant sites. These data show that a sporadic disease may be explained by somatic changes in a gene causing rare, inherited forms and pinpoint TIE2 pathways as potential therapeutic targets for venous malformations.
Germline substitutions in the endothelial cell tyrosine kinase receptor TIE2 (encoded by TEK) cause a rare, inherited form of venous anomaly known as a mucocutaneous venous malformation (VMCM; refs. 1-3 and V.W., N.L., M.U., A. Irrthum, L.M.B. et al., unpublished data). We identified a somatic 'second hit' causing loss of function of TIE2 in a resected VMCM and assessed whether such localized, tissue-specific events have a role in the etiology of sporadic venous malformations, which are far more common. We identified eight somatic TEK mutations in lesions from 28 of 57 individuals (49.1%) with sporadic venous malformations; the mutations were absent from the individuals' blood and control tissues. The somatic mutations included one causing a frequent L914F substitution and several double mutations in cis, all of which resulted in ligand-independent TIE2 hyperphosphorylation in vitro. When overexpressed in human umbilical vein endothelial cells, the L914F mutant was abnormally localized and responded to ligand, in contrast to wild-type TIE2 and the common, inherited R849W mutant, suggesting that the mutations have distinct effects. The presence of the same mutations in multifocal sporadic venous malformations in two individuals suggests a common origin for the abnormal endothelial cells at the distant sites. These data show that a sporadic disease may be explained by somatic changes in a gene causing rare, inherited forms and pinpoint TIE2 pathways as potential therapeutic targets for venous malformations.
The vascular endothelial cell-specific receptor tyrosine kinase TIE2 (MIM600221) has a crucial role in angiogenesis and cardiovascular development [4] [5] [6] [7] [8] [9] [10] [11] [12] . Its ligands, the angiopoietins, induce receptor dimerization and phosphorylation 13 , with Ang1 acting as an agonist and Ang2 as a context-dependent antagonist or weak agonist 14, 15 . In Supplementary Fig. 1a online). Allele-specific PCR showed that the loss, which is part of an intragenic somatic DNA deletion (see Methods), occurs on the wildtype allele and not the inherited 2545C4T mutant allele (Fig. 1b) .
Unlike inherited mutations affecting the intracellular domains of TIE2, the somatic Del-TIE2 mutant was not hyperphosphorylated in vitro, nor did it exacerbate hyperphosphorylation of R849W-TIE2 in trans (Fig. 1c) . The lack of 43 amino acids resulted in loss of cell surface expression of the receptor ( Fig. 1d and Supplementary  Fig. 1d ), as well as its inability to bind Ang1, in contrast to wild-type and R849W-TIE2 ( Supplementary Fig. 1b,c) . When retrovirally transfected into human umbilical vein endothelial cells (HUVECs), Del-TIE2 was retained in the endoplasmic reticulum and showed no ability to respond to Ang1 by increased phosphorylation or translocation and clustering ( Fig. 2 and Supplementary Fig. 1e ). It is probable that Del-TIE2 is unable to fold into its native form, resulting in defective protein trafficking and endoplasmic reticulum retention 18 . Thus, the somatic Del mutation acts as a null allele, causing local loss of function of wild-type TIE2.
The identification of a second hit in VMCM tissue led us to the hypothesis that somatic changes in TEK could also be etiopathogenic for common sporadic venous malformations. We screened blood DNA from 57 individuals with sporadic venous malformations, most of whom had extensive unifocal lesions, typical of the sporadic form 19 (Fig. 3a) . Histologically, the lesions were characterized by enlarged venous channels with patchy smooth muscle cell layers (Fig. 3b) , and thin, continuous TIE2-positive endothelial cell layers (Fig. 3c-e) . We did not detect any TEK mutations in blood DNA. To test for somatic changes, we screened DNA from 62 venous malformations from the same 57 individuals and identified eight missense substitutions in exon 17 in 30 lesions from 28 individuals (49.1%; described in Fig. 3 and Supplementary Table 1 online). In 24 of the 30 mutation-positive lesions, from 24 (85.7%) of 28 individuals, we identified a change from CTT to TTT at codon 914 (encoding a L914F substitution; Fig. 4a and Supplementary Fig. 2a and Table 1 online). In the other six lesions, including two each from two individuals with multifocal venous malformations (Fig. 3f,g ), we detected two mutations in cis (on the same allele; see Methods and Supplementary  Fig. 2b -e and Table 1 ). Each encoded an alteration in Tyr897 in the first tyrosine kinase domain, in combination with another change bordering or within the kinase insert domain: Y897H and R915C, Y897F and R915L, Y897C and R915C, or Y897S and S917I (Figs. 3f,g and 4b,c and Supplementary Table 1 ). The necessity for two mutations on the same allele to confer pathogenicity is uncommon but has been described for lung cancer-associated mutations affecting the tyrosine kinase domain of the epidermal growth factor receptor 20 . The four individuals with double mutations showed no clinical differences (Supplementary Table 1 ) except for the occurrence of multiple lesions in two of the individuals. Both individuals had double mutations in common between the two lesions assessed, independent of location, suggesting a common cellular (rather than individual and localized) origin for the multifocal venous malformations; however, the mutations were not detectable in blood DNA (Fig. 3f,g ). The multiple lesions could be attributed to common endothelial progenitor cells circulating to these distinct sites. Late-developing lesions could have their origins in a stem cell niche, where some cells with the capacity for self-renewal and differentiation carry postzygotic mutations 21 , or could result from circulating endothelial cells sloughed off from a primary lesion. Resections, however, do not seem to result in greater development of additional lesions. We found no changes in exon 17 in 90 control tissues from unrelated individuals, including resected skin, hemangiomas and lymphatic and vascular malformations (P ¼ 9.006 Â 10 -15 by twotailed Fisher exact test), indicating that the TEK substitutions are not common, unassociated somatic changes.
We next looked for TEK mutations in cDNA from 26 of the 30 mutation-positive tissues. We detected expression of both wild-type and mutant alleles. To estimate their relative levels, we conducted semiquantitative minisequencing on a large subset of DNAs and cDNAs. These included 11 of the 24 lesions with L914F and at least 1 lesion with each of the double mutations (Supplementary Table  1 ; see Supplementary Fig. 3 online for sample chromatograms and Supplementary Table 2 online for raw data). The presence of the mutant alleles, relative to the wild-type allele, was consistently enhanced in cDNA compared to DNA (1.8-to 18-fold; Supplementary Tables 1 and 2 ). In addition, mutant alleles were not detectable by this method in two DNAs but were robustly expressed in the cDNAs. The most frequent sporadic venous malformation alteration, L914F, was the only change that occurred alone and has not been identified in the germline in VMCM, suggesting that it is strongly deleterious. It may nevertheless require an additional hit for lesion formation: in 7 (64%) of the 11 tissues assessed, the relative level of expressed L914F-TIE2 was 58%-92% of the total, arguing for overexpression of the mutant or loss of the wild type by an unknown mechanism. The double mutations were also enriched in cDNA, to a lesser extent (Supplementary Table 1) . We compared the relative abundance of pairs of cis mutations in tissues to determine their order of occurrence (see Methods), which seemed to be fairly even; Tyr897 mutations appeared first in lesions from two patients, and the other cis mutations (R915C or R915L) occurred first in two others with multifocal lesions. The difference between mutations constituting each pair was small (within 10% of each other; Supplementary Table 1) , accounting for the predominance of double mutants obtained by cloning.
The somatic substitution sites, located within the first tyrosine kinase domain (Tyr897, Leu914 and Arg915) or the kinase insert domain (Ser917) of TIE2 (Fig. 4a-c) 22 , are highly conserved between receptor tyrosine kinases across species, and bioinformatic analyses predicted weakly to strongly damaging effects on protein function (Supplementary Table 3 online). L914F induced higher ligandindependent receptor phosphorylation than did the common germline substitution R849W (fold increase of 12.7 ± 5.8 (mean ± s.d.) versus 4.2 ± 1.6 over wild type; Fig. 4d and Supplementary Fig. 4 online). Double mutations had stronger, roughly additive effects than did constituent single mutations, with each Tyr897 substitution being the weaker of the pair ( Fig. 4e and Supplementary Fig. 4 ). There was no discernable association between clinical phenotype and level of hyperphosphorylation (Supplementary Table 1) .
To compare the effects of wild-type TIE2 and the most frequent inherited (R849W) and somatic (L914F) mutants, we studied their subcellular localization and activation with or without activating Ang1 ligand (Figs. 5 and 6 ). In the absence of ligand, wild-type and R849W-TIE2 were distributed evenly on cell membranes, with an occasional and slight increase in perinuclear TIE2 immunoreactivity and no phosphorylated TIE2 (P-TIE2)-specific staining observed (Fig. 5a,b and Supplementary Fig. 1e ). In contrast, L914F-TIE2 showed strong perinuclear accumulation and ligand-independent activation in a distinct compartment near the nucleus (Fig. 5c ). We and others have shown that Ang1 binding induces TIE2 clustering and translocation to cell edges 23, 24 . We observed this in the majority of cells expressing wild-type and R849W-TIE2 (85.8 ± 3.6% and 84.8 ± 7.6%, respectively; Fig. 5d ,e) but only in a subset of HUVECs transfected with L914F-TIE2 (12.5 ± 4.1%), in which the protein was largely found in a punctate pattern dispersed over the plasma membrane (Fig. 5f) . In mobile cells, Ang1-activated TIE2 accumulated in the trailing edge and retraction fibers (Fig. 5d) . R849W-TIE2 was more activated in retraction fibers than was wild-type TIE2 in response to Ang1; L914F-TIE2 was present in fibers at levels similar to those observed with R849W-TIE2 ( Fig. 5d-f ). Within fibers, wild-type TIE2 was typically phosphorylated in the distal ends and TIE2-containing nodules (Supplementary Fig. 5a online), whereas R849W-TIE2 showed higher phosphorylation intensity all along ( Supplementary Fig. 5b,d ). L914F-TIE2 was also phosphorylated along the fibers, significantly more than wild-type TIE2 (P o 0.001) but less than R849W-TIE (P o 0.001; Supplementary Fig. 5c,d ).
To investigate the perinuclear compartmentalization of L914F-TIE2 in greater detail, we stained HUVECs overexpressing L914F-TIE2 with Golgi and endoplasmic reticulum markers. No P-TIE2 staining was observed in the Golgi of HUVECs transfected with wild-type TIE2 (Fig. 6a) or in the majority of R849W-TIE2-expressing cells ( Fig. 6b ; weak perinuclear P-TIE2 staining detected in 3.2 ± 2% of cells). In contrast, L914F-TIE2 activation was seen in the Golgi in the majority of cells (73.2 ± 7% of cells; Fig. 6c ). L914F-TIE2 was also retained in the endoplasmic reticulum of both unstimulated (Fig. 6d) and Ang1-stimulated (Fig. 6e) cells. Unlike Del-TIE2, however, L914F-TIE2 was not exclusively intracellular, as Ang1 did induce L914F-TIE2 clustering (albeit incomplete) and translocation to cell-cell junctions, cell edges and retraction fibers, where its activation level was above that of wildtype TIE2 (Figs. 5d-f and 6e and Supplementary Fig. 5c,d) . Endoplasmic reticulum retention of L914F-TIE2 may be phosphorylation dependent (in contrast to the less strongly phosphorylated R849W-TIE2), as is the case with other human disease-associated mutant receptor tyrosine kinases, including KIT, FLT-3 and FGFR3 (refs. 25-27) . Thus, the common inherited and sporadic mutations both profoundly affect TIE2 activation, as well as response to ligand, and may act in overlapping yet distinct ways to potentiate the pathogenesis of venous malformations.
Together, our findings show that somatic mutations in TEK cause common, sporadic venous malformations, allowing us to generalize findings from a rare, inherited form of a vascular anomaly to its far more frequent sporadic counterpart. This may be true for other disorders, so somatic screens may be useful for the numerous noninherited vascular anomalies of unknown etiology. Finally, the implication of TIE2 in sporadic venous malformations greatly broadens the potential utility of therapeutic treatments that inhibit angiogenesis in general and the TIE2 signaling pathway in particular. (a-f) Sparse HUVECs expressing WT, R849W-or L914F-TIE2 were stimulated for 1 h with Ang1 or left unstimulated and stained with antibodies to total TIE2 and P-TIE2. Boxed areas are magnified (Â6) on right. a-c, In unstimulated cells expressing WT and R849W-TIE2, TIE2 was distributed evenly on cell membranes, with no P-TIE2-specific staining. In contrast, more L914F-TIE2 immunostaining was observed in the perinuclear area, where L914F-TIE2 was activated, as detected by P-TIE2 staining (c, long arrows). Without Ang1, neither cell edges nor cellular extensions showed P-TIE2-specific staining (small arrows). (d-f) In response to Ang1 stimulation, TIE2 was activated and translocated to the cell rear (arrowheads) and retraction fibers (small arrows, right). Ang1 promoted WT activation and translocation to the cell rear (d). R849W-TIE2 showed enhanced phosphorylation in retraction fibers (e, small arrow) compared to WT TIE2 (d, small arrow). Ang1 induced punctate L914F-TIE2 clustering (thick arrows) and lesscomplete translocation to the cell rear (f). Scale bars, 20 mm.
METHODS
Subject recruitment. Fifty-seven individuals with sporadic venous malformations were recruited in collaboration with the Vascular Anomalies Center, Cliniques Universitaires Saint-Luc (Brussels, Belgium). Informed consent was obtained from all participants before enrolment, as approved by the ethical committee of the Medical Faculty at the Université catholique de Louvain.
DNA and RNA samples. Tissues were collected in liquid nitrogen immediately after resection. DNA was extracted from frozen tissue and peripheral leukocytes using a Puregene DNA extraction kit (Gentra). RNA was extracted from frozen tissue using Tripure (Roche), and cDNA synthesis was done using an iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer's instructions.
Mutational analysis of VMCM tissue. Tissue and lymphoblast RNA from one individual (SaI.4; ref. 1) was extracted, and cDNA was synthesized as described above. Five overlapping amplicons of B1 kb covering the entire TEK coding sequence (3.5 kb) were amplified and sized on agarose gels. PCR products were resolved on 1% agarose gels. To determine whether the somatic deletion and 2545C4T germline mutation are allelic, allele-specific PCR was done with reverse primers specific for the wild-type or mutant allele in exon 15 and a common forward primer in exon 2. The wild-type product was 2,276 bp, whereas the mutant product was 2,147 bp (Fig. 1b) . Conditions for the 2545C4T (R849W) allele-specific PCR have been described previously 1 . After sequencing an amplicon spanning exons 3 and 4 in both blood and tissue DNA, we observed loss of heterozygosity in the tissue for a novel SNP (from T/C in blood to T in tissue) in TEK intron 3 at position 27159180 on chromosome 9, indicating that the identified loss in the ligand binding domain is part of an intragenic somatic DNA deletion rather than the result of aberrant splicing caused by a single nucleotide change.
Full-length human TEK cloning and overexpression. The 3.5-kb human TEK cDNA, with 50 bp of 5¢ UTR and 60 bp of 3¢ UTR, was cloned into the XhoI and NotI sites of pcDNA3.1/Zeo(-) (Invitrogen). To generate mutants, tissue cDNAs were used as templates to amplify regions around the respective mutations (or the deleted region). These were inserted into the full-length TEK construct to replace the wild-type fragment, using appropriate unique flanking restriction sites. The wild-type and mutant constructs were sequenceverified and expressed in Cos7 cells. The ability of the constructs to cause ligand-independent hyperphosphorylation of the receptor was tested by immunoblotting with antibodies to phosphotyrosine (PY-99; Santa Cruz Biotechnology) or Tyr1102/1108-phosphorylated TIE2 (Calbiochem), followed by stripping and reprobing with antibody to total TIE2 (C-20; Santa Cruz Biotechnology; see Supplementary Methods online). Immunohistochemistry. Standard protocols were used. Briefly, 5-mm sections were deparaffinized using Histosafe (Yvsolab) and rehydrated in propanol and then in water. Endogenous peroxidase was blocked by incubation in 0.3% H 2 O 2 for 30 min, and antigens were retrieved using citrate buffer (pH 5. Mutation analysis of the TEK gene in sporadic venous malformations. The 23 exons of the TEK gene, including exon-intron boundaries, were PCRamplified from genomic DNA. The amplicons were screened by denaturing high-performance liquid chromatography on the WAVE 3500 HS system (Transgenomic). For each sample showing an abnormal elution profile, PCR amplification of that exon was repeated, followed by sequencing on a CEQ 2000 fluorescence capillary sequencer (Beckman Coulter) to identify the nucleotide changes. These were confirmed by allele-specific PCR or by enzymatic digestion of a separately amplified PCR product ( Supplementary Fig. 2 ). To find mutations in exon 17 of TEK in tissue cDNA, direct sequencing of PCR products was carried out for each individual with a TEK mutation, using primers for sequences in exons 15 and 18. Where double mutations occurred, allele-specific PCR was done on DNA using a common forward and specific reverse primer for the more distal mutant residue (915 or 917). This product was sequenced to assess whether the mutations occurred in cis (product with mutation at residue 897) or trans (wild type at residue 897; Supplementary  Fig. 2 ). For confirmation, each double-mutant sample (and two carrying the L914F substitution) was PCR-amplified for exon 17 on tissue DNA using Pfu proofreading polymerase, followed by cloning and sequencing of a minimum of 24 clones each, to obtain at least two carrying the mutant allele(s). Semiquantitative estimation of prevalence of mutant alleles in DNA and RNA. For a large subset of venous malformations, the SNaPshot minisequencing assay (Applied Biosystems) was conducted according to the manufacturer's instructions. Briefly, PCR amplification of exon 17 was carried out in duplicate (with Pfu proofreading and Taq polymerases) from both tissue DNA and cDNA. Amplicons were cleaned by shrimp alkaline phosphatase and ExoI treatment. A forward or reverse primer stopping just short of the mutation site was used in a single-base extension reaction with fluorescence-labeled ddNTPs on cleaned amplicons (see Supplementary Table 1 for primer sequences). The products were treated with shrimp alkaline phosphatase and run on an ABI 3130xl genetic analyzer (Applied Biosystems). The peak colors ( Supplementary  Fig. 3 ) and the ratios of allele peak heights (Supplementary Table 1 ) reflect the composition of the template amplicon, allowing for an estimation of the relative abundance of mutant to wild-type alleles. The absolute peak heights reflect amplicon abundance, which do not alter allele ratios. Full-length wildtype or mutant TEK plasmid constructs were used as controls; 50:50 mixtures of these provided the heterozygote allele peak-height ratio, to which ratios obtained from tissues were normalized (Supplementary Table 1 ). The relative levels of pairs of cis mutations in tissues were compared to each other. Increased presence of one mutation compared to the other could be imputed to reflect its precedence: the occurrence of the first in a set of cells is followed by the occurrence of the second in a subset of these cells. SNaPshot data was corroborated by large-scale cloning and sequencing of DNA from lesion number 28b. We obtained 5 clones with the double substitutions Y897C and R915C, 6 with R915C alone and none with Y897C alone, of 80 clones total, confirming the SNaPshot data (5% for Y897C versus 11% for R915C). By these criteria, R915C may have occurred first.
HUVEC cell culture, TIE2 overexpression and immunofluorescence. Cell culture, retrovirus-based TIE2 transfection, immunofluorescence staining and confocal microscopy were done as previously described 24 .
Statistics. The percentage of cells with P-TIE2 in the perinuclear area was calculated based on immunofluorescence staining with antibodies to Tyr992-phosphorylated TIE2 (Cell Signaling Technology). The proportion of cells showing Ang1-induced TIE2 clustering and translocation was calculated based on the presence of TIE2 clusters, their arrangement in filamentous structures and translocation to retracting cell edges or cell-cell contacts. At least 320 cells were counted in each group, in three independent experiments run in duplicate.
Accession numbers. OMIM: VMCM, #600195; TEK, *600221. GenBank: TEK, NM_000459.
Note: Supplementary information is available on the Nature Genetics website.
